Results 21 to 30 of about 1,876,096 (308)

Pulmonary hypertension [PDF]

open access: yesCanadian Journal of Cardiology, 2010
Abstract Symptoms of unexplained exertional breathlessness or symptoms out of proportion to coexistent heart or lung disease should alert the clinician to the possibility of pulmonary hypertension, and the condition should be actively sought in patients with known associated conditions, such as scleroderma, hypoxic lung disease, liver ...
Benjamin, Hibbert   +4 more
openaire   +3 more sources

Temporal Trends in Diagnostic Hemodynamics and Survival of Patients with Pulmonary Hypertension: A Single-Center Study

open access: yesLife, 2023
Advances in the diagnosis and treatment of pulmonary hypertension (PH) have gradually improved the disease course. This retrospective cohort study aims to explore the diagnostic hemodynamic profile and survival of PH patients and their temporal changes ...
Georgios E. Papadopoulos   +12 more
doaj   +1 more source

Pulmonary hypertension: evolution of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension [PDF]

open access: yesJournal of Thoracic Disease, 2016
On May 16 th , 2016, Nick H. Kim, MD [University of California San Diego (UCSD), Division of Pulmonary, Critical Care & Sleep Medicine] delivered his keynote presentation outlining the current state of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
Anderson, Ryan J   +2 more
openaire   +5 more sources

Right heart size and function significantly correlate in patients with pulmonary arterial hypertension – a cross-sectional study

open access: yesRespiratory Research, 2018
Background The objective of this study was to assess, whether right atrial (RA) and ventricular (RV) size is related to RV pump function at rest and during exercise in patients with pulmonary arterial hypertension (PAH).
Lukas Fischer   +12 more
doaj   +1 more source

Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension

open access: yesBMC Pulmonary Medicine, 2017
Background Chronic inflammation emerges as a feature of the pathogenesis of pulmonary arterial hypertension (PAH) in experimental models. Alterations of circulating cell subsets have been observed in patients with PAH.
Lars Harbaum   +9 more
doaj   +1 more source

Impact of targeted pulmonary arterial hypertension therapies in severe pulmonary hypertension in chronic lung diseases

open access: yesERJ Open Research, 2023
Research questions Patients with severe pulmonary hypertension associated with chronic lung disease have a poor prognosis. Targeted pulmonary arterial hypertension therapies might improve exercise capacity and outcome, but there are no guidelines on ...
Romain Naud   +10 more
doaj   +1 more source

Sotatercept for the Treatment of Pulmonary Arterial Hypertension.

open access: yesNew England Journal of Medicine, 2021
BACKGROUND Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes.
M. Humbert   +17 more
semanticscholar   +1 more source

A case of Beauveria bassiana keratitis confirmed by internal transcribed spacer and LSU rDNA D1–D2 sequencing

open access: yesNew Microbes and New Infections, EarlyView., 2014
Abstract We describe a case of fungal keratitis due to Beauveria bassiana in a farmer with Fuchs' dystrophy, treated with amphotericin B. Surgery with penetrating keratoplasty was necessary to resolve the lesions. Susceptibility testing and molecular sequencing permitted the identification and treatment of this rare aetiological agent of invasive ...
M. Ligozzi   +8 more
wiley   +1 more source

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer

open access: yesAnnals of Gastroenterological Surgery, Volume 7, Issue 1, Page 81-90, January 2023., 2023
XELOXIRI neoadjuvant chemotherapy appears to be feasible and efficacious for patients with LARC. Although neoadjuvant XELOXIRI alone did not yield our expected pCR rate, the local recurrence rate, 3‐year DFS and measures of safety met current standards.
Chu Matsuda   +16 more
wiley   +1 more source

ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension

open access: yesScience Translational Medicine, 2020
ACTRIIA-Fc, an activin and GDF8/11 ligand trap, improves hemodynamics and exerts antiremodeling effects in experimental pulmonary hypertension. Remedying pulmonary vascular remodeling Alterations in bone morphogenetic protein, growth and differentiation ...
L. Yung   +20 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy